```html

Yttrium‑90 Radioembolization Complications: A Complete Medical Guide

Overview

Yttrium‑90 (Y‑90) radioembolization is a minimally invasive form of internal radiation therapy (also called selective internal radiation therapy, SIRT) used primarily to treat primary or metastatic liver cancer, such as hepatocellular carcinoma (HCC) and colorectal‑liver metastases. Tiny glass or resin microspheres loaded with the radioactive isotope Y‑90 are delivered through a catheter into the hepatic artery, where they lodge in the tumor’s microvasculature and emit high‑energy beta radiation.

While the procedure is generally safe, patients can experience a spectrum of post‑procedural complications ranging from mild (fatigue, abdominal discomfort) to serious (radiation‑induced liver disease, non‑target embolization). Understanding these complications helps patients recognize early warning signs, seek timely care, and collaborate with their treatment team.

Who is affected? Most candidates are adults with unresectable liver tumors who have adequate liver function (Child‑Pugh A or B) and preserved performance status (ECOG ≤2). Approximately 5–10 % of patients undergoing Y‑90 therapy develop clinically significant complications that require medical intervention <sup>1</sup>.

Prevalence of specific complications (based on multicenter registries, 2020‑2023):

• Post‑embolization syndrome (fever, nausea, pain): 30–40 %.
• Radiation‑induced liver disease (RILD): 3–5 %.
• Gastro‑intestinal ulceration from non‑target embolization: 1–2 %.
• Portal vein thrombosis: <1 %.
• Transient elevations in liver enzymes: up to 70 % (usually mild).

Symptoms

Complications may manifest hours to weeks after the procedure. The table below lists the most common symptoms and what they typically indicate.

Symptom	Possible Underlying Issue	Typical Onset
Fever (≥38 °C) & chills	Post‑embolization syndrome or infection	Within 24‑48 h
Right upper‑quadrant (RUQ) or epigastric pain	Inflammation of liver capsule, tumor necrosis	Hours‑days
Nausea / vomiting	Post‑embolization syndrome or gastric ulcer	24‑72 h
Fatigue / malaise	Systemic radiation effect	Days‑weeks
Jaundice (yellowing of skin/eyes)	RILD or biliary obstruction	1‑4 weeks
Abdominal distension / ascites	Severe RILD, portal hypertension	2‑6 weeks
Dark stools or melena	Upper GI ulceration from non‑target embolization	Within 1‑2 weeks
Upper‑right shoulder pain	Irritation of diaphragm (phrenic nerve)	First few days
Shortness of breath	Fluid overload, pulmonary embolism	Variable
Elevated liver enzymes (ALT, AST, ALP, GGT)	Hepatocellular injury, RILD	Days‑weeks

Causes and Risk Factors

Primary Causes

• Radiation dose to normal liver tissue – Excessive microsphere deposition outside the tumor bed can damage healthy hepatocytes, leading to RILD.
• Non‑target embolization – Microspheres may travel to the stomach, duodenum, or pancreas if arterial collaterals are not adequately embolized before treatment, causing ulceration or bleeding.
• Ischemic injury – Temporary occlusion of arterial flow during catheterization can produce transient pain and inflammation.

Risk Factors that Increase Complication Likelihood

• Pre‑existing liver dysfunction (Child‑Pugh B/C).
• Large tumor burden (>50 % of liver volume) – higher radiation to spared parenchyma.
• Prior liver-directed therapies (TACE, RFA) that have already compromised hepatic reserve.
• Portal vein thrombosis – reduces compensatory blood flow.
• Unrecognized arterial anastomoses to the gastrointestinal tract.
• Age >75 years, diabetes, or cirrhosis (especially alcoholic or NASH).

Diagnosis

Diagnosis combines clinical assessment, laboratory testing, and imaging. Prompt recognition is essential because many complications are reversible if treated early.

Initial Evaluation

• History and physical exam – Focus on timing and character of symptoms, abdominal tenderness, jaundice, and signs of infection.
• Laboratory panel – CBC, comprehensive metabolic panel, coagulation profile, and specific liver function tests (ALT, AST, bilirubin, ALP).

Imaging Studies

• Contrast‑enhanced CT or MRI (portal‑venous phase) – Detects hepatic infarction, tumor response, ascites, or non‑target embolization.
• 99mTc‑macroaggregated albumin (MAA) scan – Performed pre‑procedure; post‑procedure, it can be repeated to assess unexpected shunting.
• Endoscopy (EGD) – Indicated if upper GI bleeding or ulcer symptoms arise.
• Doppler ultrasound – Evaluates portal vein patency and liver blood flow.

Specific Diagnostic Criteria

Radiation‑induced liver disease (RILD) is defined by:*

• Elevated bilirubin >2 mg/dL or a rise >2 mg/dL from baseline,
• Ascites or hepatomegaly without tumor progression,
• Symptoms occurring 2–12 weeks after Y‑90 administration,
• Absence of infection or biliary obstruction.

Treatment Options

Treatment is symptom‑driven and aims to preserve remaining liver function.

1. Supportive Care

• Analgesia – Acetaminophen (≤2 g/day) or short courses of short‑acting opioids for severe pain.
• Antipyretics – Acetaminophen or ibuprofen (if renal function allows) for fever.
• Anti‑emetics – Ondansetron, metoclopramide, or prochlorperazine.
• Hydration – Intravenous isotonic fluids to maintain renal perfusion and aid toxin clearance.

2. Specific Medical Therapies

• Corticosteroids – Prednisone 0.5 mg/kg/day for severe RILD (taper over 4‑6 weeks) as recommended by the European Association for the Study of the Liver (EASL) <sup>2</sup>.
• Proton‑pump inhibitors (PPIs) – For prophylaxis against GI ulceration when non‑target embolization is suspected.
• Broad‑spectrum antibiotics – If infection (e.g., hepatic abscess) is confirmed by imaging or cultures.
• Anticoagulation – Low‑molecular‑weight heparin followed by oral anticoagulant if portal vein thrombosis is diagnosed, balancing bleed risk.

3. Interventional Procedures

• Transjugular intrahepatic portosystemic shunt (TIPS) – Considered for refractory ascites or portal hypertension secondary to RILD.
• Endoscopic therapy – Hemostatic clipping, injection therapy, or radiofrequency ablation for bleeding gastric/duodenal ulcers.
• Percutaneous drainage – For large hepatic collections or abscesses.

4. Lifestyle & Long‑Term Management

• Low‑sodium diet (≤2 g Na⁺/day) to control ascites.
• Avoid alcohol and hepatotoxic drugs (e.g., high‑dose acetaminophen, certain antibiotics).
• Vaccinations against hepatitis A & B if not immune.
• Regular exercise as tolerated – improves portal flow and overall wellbeing.

Living with Yttrium‑90 Radioembolization Complication

Adapting daily life while managing side effects can be challenging. Below are practical tips.

Daily Monitoring

• Check temperature twice daily for the first two weeks.
• Record weight; a gain of >2 kg in a week may signal fluid accumulation.
• Track any change in stool color (black, tarry stools) or vomiting blood.

Nutrition

• Eat small, frequent meals rich in protein (lean meat, legumes, dairy) to support liver regeneration.
• Limit high‑fat, fried, and processed foods which increase hepatic workload.
• Stay hydrated – 2–3 L of water or low‑sugar fluids per day unless fluid restriction is prescribed.

Activity

• Gentle walks (10‑15 minutes) twice daily are encouraged unless you feel dizzy or fatigued.
• Avoid heavy lifting or straining for at least 4 weeks post‑procedure.

Medication Adherence

• Use a pill organizer or smartphone reminder to take prescribed steroids, PPIs, or antibiotics on schedule.
• Never stop steroids abruptly; taper as directed.

Follow‑up Schedule

• First clinic visit: 1–2 weeks after Y‑90 to assess early complications.
• Imaging (triphasic CT or MRI) at 4‑6 weeks to evaluate tumor response and liver health.
• Quarterly labs for the first 6 months, then semi‑annual if stable.

Prevention

Many complications can be minimized with thorough pre‑procedure planning and post‑procedure care.

• Detailed angiography & prophylactic embolization of arteries that communicate with the stomach or duodenum to prevent non‑target delivery.
• Accurate dosimetry – Use personalized dosimetry (MIRD, partition model) to keep radiation dose to healthy liver < 30 Gy.
• Optimize liver function – Treat underlying hepatitis, control ascites, and correct coagulopathy before the procedure.
• Patient education – Provide written instructions on warning signs and when to call the clinic.
• Vaccination and infection prophylaxis – Hepatitis A/B vaccines and, when appropriate, prophylactic antibiotics for high‑risk patients.

Complications if Untreated

When complications are ignored or inadequately managed, they can progress to life‑threatening conditions.

• Severe RILD – May lead to hepatic failure, encephalopathy, and need for liver transplantation.
• Uncontrolled GI bleeding – Can cause massive hemorrhage, anemia, and shock.
• Portal vein thrombosis – Increases portal hypertension, ascites, and variceal bleeding.
• Infection (hepatic abscess) – Sepsis, multiorgan failure.
• Chronic pain and reduced quality of life – Limits mobility, nutrition, and mental health.

When to Seek Emergency Care

---

References:

1. Mayo Clinic – Radioembolization (Y‑90)
2. European Association for the Study of the Liver – Guidelines on Radiation‑Induced Liver Disease
3. CDC – Hepatitis Statistics
4. Cleveland Clinic – Y‑90 Radioembolization Overview
5. PubMed – Multicenter Registry of Y‑90 Complications, 2022

```